EA201600093A1 - Дигидроксифенильные нейромедиаторные соединения, композиции и способы - Google Patents
Дигидроксифенильные нейромедиаторные соединения, композиции и способыInfo
- Publication number
- EA201600093A1 EA201600093A1 EA201600093A EA201600093A EA201600093A1 EA 201600093 A1 EA201600093 A1 EA 201600093A1 EA 201600093 A EA201600093 A EA 201600093A EA 201600093 A EA201600093 A EA 201600093A EA 201600093 A1 EA201600093 A1 EA 201600093A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- dihydroxiphenilic
- neuromediator
- connections
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- -1 dihydroxyphenyl Chemical group 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361843549P | 2013-07-08 | 2013-07-08 | |
| US201462010098P | 2014-06-10 | 2014-06-10 | |
| PCT/US2014/045731 WO2015006315A1 (en) | 2013-07-08 | 2014-07-08 | Dihydroxyphenyl neurotransmitter compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201600093A1 true EA201600093A1 (ru) | 2016-08-31 |
Family
ID=52133230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201600093A EA201600093A1 (ru) | 2013-07-08 | 2014-07-08 | Дигидроксифенильные нейромедиаторные соединения, композиции и способы |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20150011630A1 (https=) |
| EP (2) | EP3611159B1 (https=) |
| JP (1) | JP6567515B2 (https=) |
| KR (1) | KR20160041912A (https=) |
| CN (1) | CN105473545B (https=) |
| AU (2) | AU2014287418A1 (https=) |
| BR (1) | BR112016000338A8 (https=) |
| CA (1) | CA2917159C (https=) |
| CL (1) | CL2016000019A1 (https=) |
| EA (1) | EA201600093A1 (https=) |
| HK (1) | HK1221713A1 (https=) |
| IL (2) | IL243488A0 (https=) |
| MX (1) | MX384131B (https=) |
| PE (1) | PE20160556A1 (https=) |
| SG (2) | SG10201800166UA (https=) |
| WO (1) | WO2015006315A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3000460T3 (en) * | 2016-08-30 | 2025-02-28 | Theravance Biopharma R&D Ip Llc | Ampreloxetine for use in the treatment of neurogenic orthostatic hypotension |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| JP7682097B2 (ja) | 2019-03-27 | 2025-05-23 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニスト及びそれを使用する方法 |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| WO2021081292A1 (en) * | 2019-10-25 | 2021-04-29 | Curasen Therapeutics, Inc. | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS |
| CA3161376A1 (en) | 2019-12-18 | 2021-06-24 | Anthony P. FORD | Methods for improving neurological diseases and disorders |
| WO2021247963A1 (en) * | 2020-06-05 | 2021-12-09 | Senda Biosciences, Inc. | (s)-alpha-fluoromethyltyrosine as decarboxylase inhibitors for use in the treatment of hypotension |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0084928B1 (en) * | 1982-01-14 | 1985-09-11 | Sumitomo Chemical Company, Limited | Process for producing threo-3-(3,4-dihydroxyphenyl)serine |
| CA1223602A (en) | 1983-05-25 | 1987-06-30 | Naohito Ohashi | Process for producing 3-(3,4-dihydroxyphenyl) serine |
| JP3764179B2 (ja) | 1994-07-05 | 2006-04-05 | 克寛 西野 | 運動・意識または言語障害の機能改善剤 |
| DE19619510A1 (de) | 1995-05-18 | 1996-11-21 | Sumitomo Chemical Co | Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin |
| JP3489319B2 (ja) | 1996-03-12 | 2004-01-19 | 住友化学工業株式会社 | カルボン酸誘導体、その製造法および用途 |
| JPH115738A (ja) | 1997-06-15 | 1999-01-12 | Katsuhiro Nishino | 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤 |
| US6376531B1 (en) * | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| DE10261807A1 (de) * | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel |
| WO2005084330A2 (en) | 2004-03-02 | 2005-09-15 | Synergia Pharma, Inc. | Compositions and methods for treating nasal congestion |
| CA2642593C (en) * | 2006-02-17 | 2014-11-04 | Birds Pharma Gmbh Berolina Innovative Research & Development Services | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| ES2500053T3 (es) | 2007-03-09 | 2014-09-29 | Chelsea Therapeutics, Inc. | Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia |
| WO2008112773A2 (en) | 2007-03-12 | 2008-09-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
| JP2010526820A (ja) | 2007-05-07 | 2010-08-05 | チェルシー・セラピューティクス，インコーポレイテッド | 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物 |
| US7745665B2 (en) | 2007-06-04 | 2010-06-29 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
| WO2010054286A2 (en) * | 2008-11-10 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
| WO2010132128A1 (en) | 2009-05-14 | 2010-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease |
| EP2450343A4 (en) | 2009-07-01 | 2013-01-09 | Dainippon Sumitomo Pharma Co | PROCESS FOR PREPARING THREO-3- (3,4-DIHYDROXYPHENYL) L-SERIN |
| JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
| US20130253061A1 (en) | 2012-03-20 | 2013-09-26 | Chelsea Therapeutics, Inc. | Method of droxidopa synthesis |
-
2014
- 2014-07-08 CN CN201480042918.0A patent/CN105473545B/zh not_active Expired - Fee Related
- 2014-07-08 EP EP19188210.9A patent/EP3611159B1/en active Active
- 2014-07-08 EA EA201600093A patent/EA201600093A1/ru unknown
- 2014-07-08 PE PE2016000010A patent/PE20160556A1/es unknown
- 2014-07-08 SG SG10201800166UA patent/SG10201800166UA/en unknown
- 2014-07-08 WO PCT/US2014/045731 patent/WO2015006315A1/en not_active Ceased
- 2014-07-08 SG SG11201510764QA patent/SG11201510764QA/en unknown
- 2014-07-08 BR BR112016000338A patent/BR112016000338A8/pt not_active Application Discontinuation
- 2014-07-08 KR KR1020167003133A patent/KR20160041912A/ko not_active Withdrawn
- 2014-07-08 JP JP2016525422A patent/JP6567515B2/ja not_active Expired - Fee Related
- 2014-07-08 CA CA2917159A patent/CA2917159C/en active Active
- 2014-07-08 EP EP14822407.4A patent/EP3019467A4/en not_active Withdrawn
- 2014-07-08 MX MX2016000219A patent/MX384131B/es unknown
- 2014-07-08 HK HK16109787.0A patent/HK1221713A1/zh unknown
- 2014-07-08 US US14/325,988 patent/US20150011630A1/en not_active Abandoned
- 2014-07-08 AU AU2014287418A patent/AU2014287418A1/en not_active Abandoned
-
2016
- 2016-01-05 IL IL243488A patent/IL243488A0/en unknown
- 2016-01-07 CL CL2016000019A patent/CL2016000019A1/es unknown
-
2017
- 2017-07-21 US US15/656,035 patent/US20170319694A1/en not_active Abandoned
-
2018
- 2018-06-06 US US16/000,965 patent/US20180280511A1/en not_active Abandoned
- 2018-10-26 AU AU2018253594A patent/AU2018253594A1/en not_active Abandoned
-
2019
- 2019-05-21 IL IL266767A patent/IL266767A/en unknown
- 2019-08-01 US US16/529,187 patent/US20190374642A1/en not_active Abandoned
-
2021
- 2021-08-11 US US17/399,708 patent/US20220072131A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016000338A2 (pt) | 2017-08-22 |
| IL243488A0 (en) | 2016-02-29 |
| US20150011630A1 (en) | 2015-01-08 |
| SG11201510764QA (en) | 2016-01-28 |
| CA2917159C (en) | 2022-08-23 |
| PE20160556A1 (es) | 2016-06-11 |
| US20180280511A1 (en) | 2018-10-04 |
| EP3019467A4 (en) | 2017-03-15 |
| SG10201800166UA (en) | 2018-02-27 |
| IL266767A (en) | 2019-07-31 |
| KR20160041912A (ko) | 2016-04-18 |
| CA2917159A1 (en) | 2015-01-15 |
| CN105473545A (zh) | 2016-04-06 |
| AU2018253594A1 (en) | 2018-11-22 |
| US20170319694A1 (en) | 2017-11-09 |
| EP3611159B1 (en) | 2023-01-25 |
| JP2016529228A (ja) | 2016-09-23 |
| US20220072131A1 (en) | 2022-03-10 |
| HK1221713A1 (zh) | 2017-06-09 |
| HK1216747A1 (zh) | 2016-12-02 |
| EP3019467A1 (en) | 2016-05-18 |
| US20190374642A1 (en) | 2019-12-12 |
| AU2014287418A1 (en) | 2016-01-28 |
| CN105473545B (zh) | 2017-08-04 |
| JP6567515B2 (ja) | 2019-08-28 |
| EP3611159A1 (en) | 2020-02-19 |
| BR112016000338A8 (pt) | 2020-01-07 |
| MX2016000219A (es) | 2016-05-31 |
| CL2016000019A1 (es) | 2016-11-04 |
| MX384131B (es) | 2025-03-14 |
| WO2015006315A1 (en) | 2015-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201600093A1 (ru) | Дигидроксифенильные нейромедиаторные соединения, композиции и способы | |
| EA201691945A1 (ru) | Антитела к гемагглютинину вируса гриппа типа b и способы их применения | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| MX2022011795A (es) | Moduladores de p2x7. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
| EA201692425A1 (ru) | Модифицированные биополимеры и способы их получения и использования | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| EA201791460A1 (ru) | N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA202091397A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| EA201590731A1 (ru) | Антитела к гемагглютинину и способы применения | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| EA201790461A1 (ru) | Композиции внеклеточного матрикса | |
| EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
| DOP2016000073A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 |